Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial.

[1]  J. Tardif,et al.  Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial , 2010, Circulation.

[2]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[3]  R. Califf,et al.  Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. , 2009, The New England journal of medicine.

[4]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[5]  M. Ruel,et al.  Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety , 2009, Expert opinion on drug safety.

[6]  M. Brookhart,et al.  Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery , 2008, Circulation.

[7]  R. Califf,et al.  Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). , 2008, The American journal of cardiology.

[8]  Sanjiv J. Shah,et al.  Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. , 2008, Journal of the American College of Cardiology.

[9]  P Michael Ho,et al.  Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. , 2008, American heart journal.

[10]  D. Solomon,et al.  Patterns and predictors of statin use after coronary artery bypass graft surgery. , 2007, The Journal of thoracic and cardiovascular surgery.

[11]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[12]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[13]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[14]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[15]  R. Califf,et al.  Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease , 2006, Circulation.

[16]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[17]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[18]  G. Wells,et al.  The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423] , 2005, Current controlled trials in cardiovascular medicine.

[19]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[20]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[21]  C David Naylor,et al.  A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. , 2004, The New England journal of medicine.

[22]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[23]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[24]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[25]  N. Turner,et al.  Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. , 2002, Journal of vascular surgery.

[26]  B. Hoogwerf,et al.  Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial , 2001, Circulation.

[27]  Douglas G Altman,et al.  Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries , 2001, The Lancet.

[28]  C. Tracy,et al.  American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.

[29]  T. Lüscher,et al.  HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. , 2000, Journal of the American College of Cardiology.

[30]  B. Hoogwerf,et al.  Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .

[31]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[32]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[33]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[34]  J. Rossouw.  Lipid-lowering interventions in angiographic trials. , 1995, The American journal of cardiology.

[35]  H. Daida,et al.  Relation of saphenous vein graft obstruction to serum cholesterol levels. , 1995, Journal of the American College of Cardiology.

[36]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[37]  K. Kugiyama,et al.  Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. , 1993, Circulation research.

[38]  S. Wacholder,et al.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. , 1984, The New England journal of medicine.

[39]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[40]  C. Indolfi,et al.  Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. , 2000, Journal of the American College of Cardiology.